Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of ABI-007 vs weekly paclitaxel in fluoropyrimidine-refractory unresectable/recurrent gastric cancer
jRCT2080222013Phase 3
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of nab-paclitaxel in gastric adenocarcinoma (3 arms), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
nab-paclitaxel
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on jRCT2080222013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222013.